DX&VX Enters Obesity Treatment Market Worth 170 Billion KRW

DXVX announced on the 30th that it will officially enter the obesity treatment drug market starting in June.

To this end, it will exclusively supply 22 obesity specialty drug products to hospitals, clinics, and pharmacies nationwide. In the future, the company plans to expand into metabolic disease drugs and promote domestic market cooperation with global pharmaceutical companies.

Last year, DXVX obtained the KGSP (Korea Good Supply Practice) certification for pharmaceutical distribution quality management for drug wholesale distribution and established a medical distribution division to expand its sales network to hospitals, clinics, and pharmacies. In particular, rather than simply distributing obesity specialty drugs, it plans to conduct prescription activities targeting over 1,000 customer hospitals and clinics to secure stable sales volume and profitability.

Currently, as the global obese population rapidly increases, the obesity treatment drug market is steadily growing. The global obesity prevalence rate has more than tripled since 1975, and in Korea, the obesity prevalence rate among adults and middle and high school students has been continuously increasing over the past decade. Accordingly, last year, the domestic obesity treatment drug market size reached 175.7 billion KRW, an 81.5% increase over four years from 96.8 billion KRW in 2018. The global obesity treatment drug market is also expected to grow from $3.2 billion in 2021 to $4.6 billion by 2026.

A DXVX official stated, “We plan to continuously secure and supply follow-up specialty drugs as we expand our hospital and clinic customer base,” adding, “Since we are also participating in clinical trials for new drugs targeting metabolic diseases such as diabetes and obesity at the Italian Gemelli Hospital in collaboration with our affiliate KoreItaly, we will expand our business scope through domestic and international distribution of newly developed drugs and various global pharmaceuticals, starting with this entry into the obesity drug market.”

Meanwhile, DXVX plans to launch 12 types of DXVX brand probiotics products based on microbiome technology developed by KoreItaly simultaneously in the global and domestic markets in August, so the product lineup supplied to hospitals, clinics, and pharmacies is expected to expand further.